<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26641137</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1533-4406</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>374</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Jan</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>The New England journal of medicine</Title>
          <ISOAbbreviation>N Engl J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>323</StartPage>
          <EndPage>332</EndPage>
          <MedlinePgn>323-32</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1509981</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated immunoglobulin heavy-chain variable genes. No dose-limiting toxic effects occurred during the dose-escalation portion of the study. The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), and increased weight (in 26%). Most adverse events were of grade 1 or 2. At a median follow-up of 14.3 months, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease. Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%. No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Byrd</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harrington</LastName>
            <ForeName>Bonnie</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Brien</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jones</LastName>
            <ForeName>Jeffrey A</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schuh</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Devereux</LastName>
            <ForeName>Steve</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chaves</LastName>
            <ForeName>Jorge</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wierda</LastName>
            <ForeName>William G</ForeName>
            <Initials>WG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Awan</LastName>
            <ForeName>Farrukh T</ForeName>
            <Initials>FT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Jennifer R</ForeName>
            <Initials>JR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hillmen</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stephens</LastName>
            <ForeName>Deborah M</ForeName>
            <Initials>DM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghia</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barrientos</LastName>
            <ForeName>Jacqueline C</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pagel</LastName>
            <ForeName>John M</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woyach</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Dave</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Jane</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaolin</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaptein</LastName>
            <ForeName>Allard</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lannutti</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Covey</LastName>
            <ForeName>Todd</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fardis</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>McGreivy</LastName>
            <ForeName>Jesse</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamdy</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rothbaum</LastName>
            <ForeName>Wayne</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diacovo</LastName>
            <ForeName>Thomas G</ForeName>
            <Initials>TG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Amy J</ForeName>
            <Initials>AJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Furman</LastName>
            <ForeName>Richard R</ForeName>
            <Initials>RR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02029443</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA197870</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K23 CA178183</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA09338</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA177292</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA159296</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA081534</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA095426</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA169162</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA016058</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA009338</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA197734</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01HD081281</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>N Engl J Med</MedlineTA>
        <NlmUniqueID>0255562</NlmUniqueID>
        <ISSNLinking>0028-4793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D000077329">Agammaglobulinaemia Tyrosine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C000625949">BTK protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2016 Jan 28;374(4):386-8</RefSource>
          <PMID Version="1">26816016</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2016 Jun 2;374(22):2185-6</RefSource>
          <PMID Version="1">27248633</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077329" MajorTopicYN="N">Agammaglobulinaemia Tyrosine Kinase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002872" MajorTopicYN="N">Chromosome Deletion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26641137</ArticleId>
        <ArticleId IdType="mid">NIHMS744440</ArticleId>
        <ArticleId IdType="pmc">PMC4862586</ArticleId>
        <ArticleId IdType="doi">10.1056/NEJMoa1509981</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Goede V, Fischer K, Busch R, et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. The New England journal of medicine. 2014;370:1101–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24401022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Fischer K, Fingerle-Rowson G, et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20888994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quiroga MP, Balakrishnan K, Kurtova AV, et al.  B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114:1029–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4916941</ArticleId>
            <ArticleId IdType="pubmed">19491390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herishanu Y, Perez-Galan P, Liu D, et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3031480</ArticleId>
            <ArticleId IdType="pubmed">20940416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SE, Gordon AL, Hertlein E, et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3122947</ArticleId>
            <ArticleId IdType="pubmed">21422473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponader S, Chen S-S, Buggy JJ, et al.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4916557</ArticleId>
            <ArticleId IdType="pubmed">22180443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Rooij MFM, Kuil A, Geest CR, et al.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22279054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rawlings DJ, Saffran DC, Tsukada S, et al.  Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science (New York, N Y) 1993;261:358–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8332901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Q, Zhang M, Winkelstein J, Chen SH, Ochs HD. Unique mutations of Bruton’s tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families. Human molecular genetics. 1994;3:1899–900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7849721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al.  Brief report: a point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. The New England journal of medicine. 1994;330:1488–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8164701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honigberg LA, Smith AM, Sirisawad M, et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:13075–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2919935</ArticleId>
            <ArticleId IdType="pubmed">20615965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2013;369:1278–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24066758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Brown JR, O’Brien S, et al.  Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. The New England journal of medicine. 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien S, Furman RR, Coutre SE, et al.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. The lancet oncology. 2014;15:48–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134524</ArticleId>
            <ArticleId IdType="pubmed">24332241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddocks KJ, Ruppert AS, Lozanski G, et al.  Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1:80–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4520535</ArticleId>
            <ArticleId IdType="pubmed">26182309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain P, Keating M, Wierda W, et al.  Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125:2062–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4467871</ArticleId>
            <ArticleId IdType="pubmed">25573991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubovsky JA, Beckwith KA, Natarajan G, et al.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3795457</ArticleId>
            <ArticleId IdType="pubmed">23886836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JTK, Zhou H, et al.  Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies. Nat Biotechnol. 2008;26:114–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18084279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan EL, M P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1957;53:457–81.</Citation>
        </Reference>
        <Reference>
          <Citation>Gardner HL, H B, Izumi R, et al.  ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. AACR 2014 Annual Meeting. 2014 Abstract 1744.</Citation>
        </Reference>
        <Reference>
          <Citation>Brown JR, Byrd JC, Coutre SE, et al.  Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4123414</ArticleId>
            <ArticleId IdType="pubmed">24615777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Furman RR, Liu TM, et al.  Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. The New England journal of medicine. 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4144824</ArticleId>
            <ArticleId IdType="pubmed">24869598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans EK, Tester R, Aslanian S, et al.  Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. The Journal of pharmacology and experimental therapeutics. 2013;346:219–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23709115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown J, Harb WA, Hill BT, Gabrilove G, Sharman JP, Schreeder MT, Barr P, Foran JM, Miller TP, Kelly KR, Mahadevan DR, Ma S, Barnett E, Marine J, Nava-Parada1 P, Azaryan A, Mei J, Kipps TJ. Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor. Relapsed/Refractory Chronic Lymphocytic Leukemia Blood (sup) 2013 Abstr 1630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5004476</ArticleId>
            <ArticleId IdType="pubmed">27151992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. American journal of blood research. 2013;3:71–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3555194</ArticleId>
            <ArticleId IdType="pubmed">23359016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Bojnik E, Ruppert AS, et al.  Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL) Blood. 2014;123:1207–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3931190</ArticleId>
            <ArticleId IdType="pubmed">24311722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson WH, Young RM, Schmitz R, et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature medicine. 2015;21:922–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26193343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ML, Rule S, Martin P, et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. The New England journal of medicine. 2013;369:507–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4513941</ArticleId>
            <ArticleId IdType="pubmed">23782157</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
